Authors
Latest:
Novel Proteasome Inhibitors for Multiple MyelomaMultiple new proteasome inhibitors currently in clinical or preclinical development bode well for potential future therapies for multiple myeloma, both in frontline and relapsed or refractory settings.
Latest:
Novel Antibody-Drug Conjugate Enters Phase III Trial for Metastatic TNBCInvestigators are optimistic about sacituzumab govitecan (IMMU-132), an antibody–drug conjugate that delivers the chemotherapy metabolite SN-38 to tumor cells expressing the TROP-2 receptor, for patients with relapsed/refractory TNBC.
Latest:
Dr. Chung on Adding Dietary Supplements to Chemotherapy in Pancreatic CancerVincent Chung, MD, discusses findings from a pilot study evaluating the safety of adding dietary supplements to chemotherapy in patients with unresectable pancreatic cancer.
Latest:
Dr. Picozzi on Prognostic Value of Pathologic Response to Chemo in Pancreatic CancerVincent J. Picozzi Jr, MD, discusses the prognostic value of pathologic response to neoadjuvant chemotherapy in patients with resected pancreatic cancer.
Latest:
Dr Lam on the Tumor Microenvironment in ALK Fusion+ Lung CancerVincent K. Lam, MD, discusses findings from a study profiling the tumor immune microenvironment in patients with ALK fusion–positive lung cancer and potential future directions for this research.
Latest:
Dr. Vincent Miller Describes FoundationOneVincent Miller, MD, Chief Medical Officer, Foundation Medicine, describes FoundationOne, a fully informative genomic profile that launched in 2012.
Latest:
Dr. DeVita Discusses "The Death of Cancer"In The Death of Cancer, written by Vincent T. DeVita Jr, MD, a pioneering oncologist reveals, after 50 years on the front lines of medicine, why the war on cancer is winnable, and how to get there. In an interview with OncLive hosted by Maurie Markman, MD, he speaks with DeVita on his book and his thoughts on how the field has evolved.
Latest:
Dr. Vandecaveye on Diffusion MRI for Tumor DifferentiationVincent Vandecaveye, MD, PhD, University Hospitals Leuven, discusses developments of magnetic resonance imaging, specifically diffusion MRI, as a method to differentiate tumors and disease stages.
Latest:
Dr. Ng on Immunotherapy in Micrometastatic High-Risk Soft Tissue SarcomaVincent Y. Ng, MD, discusses immunotherapy in micrometastatic high-risk soft tissue sarcoma.
Latest:
Dr. Pullarkat on Treatment Strategies in Transplant Ineligible ALLVinod A. Pullarkat, MD, clinical professor of Hematology & Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses treatment strategies in transplant ineligible acute lymphoblastic leukemia (ALL).
Latest:
Final Thoughts on New Developments and Emerging AgentsPanelists conclude by reviewing possible advancements on the horizon in AML such as the potential emergence of Menin inhibitors and bispecific T-cell engagers as well as improved methods for predicting response and preventing relapse.
Latest:
Dr. Poeschel on 6 Versus 4 Cycles of R-CHOP in Frontline DLBCLViola Poeschel, MD, department of hematology, oncology and rheumatology, Saarland University Medical School, Germany, discusses outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who were treated with 4 cycles of R-CHOP during the 2018 ASH Annual Meeting.
Latest:
Dr. Zhu on TMB in Lung CancerViola W. Zhu, MD, PhD, medical oncologist/hematologist, University of California, Irvine, discusses tumor mutational burden (TMB) in lung cancer.
Latest:
Dr. Viprakasit on the Results of the BELIEVE Trial With Luspatercept in Beta-ThalassemiaVip Viprakasit, MD, DPhil, professor of Pediatrics, and director, Thalassemia Research, Siriraj-Thalassemia Center, Siriaj Hospital, discusses the results of the multicenter BELIEVE trial with luspatercept (Reblozyl) in adult patients with β-thalassemia.
Latest:
Novel VIL Approach Reduces Complications From Regional Lymphadenectomy in MelanomaSurgical intervention is a Machiavellian endeavor: the ends justify the means. This obligates the clinician to minimize the risk of a procedure to justify the gains obtained from an intervention.
Latest:
Sitravatinib/Tislelizumab Combo Active in Advanced Ovarian CancerThe novel combination of sitravatinib and tislelizumab showed encouraging antitumor activity and a manageable safety profile in patients with advanced ovarian cancer.
Latest:
HER2+ Metastatic Breast Cancer: Unmet Needs and Future Directions in CareClosing out her discussion on HER2+ metastatic breast cancer, expert oncologist Virginia Kaklamani, MD, DSc, highlights ongoing unmet needs future directions in care.
Latest:
Frontline Atezolizumab Combo Emerges as Potential New Standard in NSCLCThe frontline regimen of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel has emerged as a potential new standard of care for the treatment of patients with metastatic nonsquamous NSCLC.
Latest:
Transplantation Using Haploidentical Donors Outperforms Matched Sibling Donors in MRD+ ALLHaploidentical donor transplantation led to stronger anti-leukemia activity compared with matched sibling donor transplantation in transplant-eligible patients with minimal residual disease–positive acute lymphoblastic leukemia.
Latest:
Expert Discusses Neoadjuvant Treatment Potential in Advanced RCCNeoadjuvant therapy is evolving as a treatment approach for patients with advanced renal cell carcinoma.
Latest:
Selecting Your Career PathMedical education and training is very intense, long, and expensive. When nearing the end of training, it is time to select a career path.
Latest:
Dr Margulis on Key Considerations When Navigating Frontline Combination Regimens in RCCVitaly Margulis, MD, discusses key disease characteristics and patient factors to consider when selecting between IO/IO vs IO/TKI treatment combinations for the management of patients with renal cell carcinoma.
Latest:
Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck CarcinomaThis study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.
Latest:
Maintaining the Pace of ProgressOver the past 40 years, since the declaration of the War on Cancer in 1971, we have seen tremendous advances in our struggle with this deadly disease.
Latest:
Dr. Subbiah on the FDA Approval of Dabrafenib/Trametinib in BRAF V600E–Mutated Solid TumorsVivek Subbiah, MD, discusses the FDA approval of dabrafenib plus trametinib for the treatment of patients with BRAF V600E–mutated unresectable or metastatic solid tumors.
Latest:
Landmark Trial Puts Robotic Surgery to the Test in Bladder CancerVivek Venkatramani, MD, and Dipen J. Parekh, MD, discuss the evolution of surgery in bladder cancer.
Latest:
Adjuvant Radiotherapy in Low-Risk Breast Cancer Patients: Review and Clinical ImplicationsOver the past several decades, breast-conserving therapy has emerged as the standard of care in the management of early-stage breast cancer.
Latest:
Dr. Tjan-Heijnen on Results of DATA Study in Breast CancerVivianne Tjan-Heijnen, MD, PhD, professor, Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Center, discusses the results of the phase III DATA study.
